Akebia Therapeutics Inc
NASDAQ:AKBA
Intrinsic Value
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. [ Read More ]
The intrinsic value of one AKBA stock under the Base Case scenario is 3.34 USD. Compared to the current market price of 1.33 USD, Akebia Therapeutics Inc is Undervalued by 60%.
Valuation Backtest
Akebia Therapeutics Inc
Run backtest to discover the historical profit from buying and selling AKBA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Akebia Therapeutics Inc
Current Assets | 118.1m |
Cash & Short-Term Investments | 42.9m |
Receivables | 39.3m |
Other Current Assets | 35.9m |
Non-Current Assets | 123.6m |
PP&E | 16m |
Intangibles | 95.1m |
Other Non-Current Assets | 12.4m |
Current Liabilities | 99.9m |
Accounts Payable | 14.6m |
Accrued Liabilities | 67.7m |
Other Current Liabilities | 17.5m |
Non-Current Liabilities | 172.4m |
Long-Term Debt | 17.2m |
Other Non-Current Liabilities | 155.2m |
Earnings Waterfall
Akebia Therapeutics Inc
Revenue
|
194.6m
USD
|
Cost of Revenue
|
-39.7m
USD
|
Gross Profit
|
154.9m
USD
|
Operating Expenses
|
-199.4m
USD
|
Operating Income
|
-44.5m
USD
|
Other Expenses
|
-7.5m
USD
|
Net Income
|
-51.9m
USD
|
Free Cash Flow Analysis
Akebia Therapeutics Inc
AKBA Profitability Score
Profitability Due Diligence
Akebia Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Akebia Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
AKBA Solvency Score
Solvency Due Diligence
Akebia Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Akebia Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AKBA Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AKBA is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 6.3 USD.
Ownership
AKBA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AKBA Price
Akebia Therapeutics Inc
Average Annual Return | -36.33% |
Standard Deviation of Annual Returns | 33.96% |
Max Drawdown | -98% |
Market Capitalization | 258.8m USD |
Shares Outstanding | 209 372 000 |
Percentage of Shares Shorted | 6.47% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
Contact
IPO
Employees
Officers
The intrinsic value of one AKBA stock under the Base Case scenario is 3.34 USD.
Compared to the current market price of 1.33 USD, Akebia Therapeutics Inc is Undervalued by 60%.